Nuvalent Inc (NUVL)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Nuvalent Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
52-Week Range
Current price 124.00 $ — 100% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 1,575.4% passed
- Share count grows by less than 3% a year 13.5% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 1,372 m net cash passed
- Operating cash flow covers the profits of the last three years 252 m failed
- Return on capital at 15% or higher, or up versus two years ago -31.4% failed
- Insiders hold at least 10% or are net buyers 2.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 0.0% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 11
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -5.50 | -6.37 – -4.69 | 11 | 5.9% | 10 |
| 12/31/2027 | -4.02 | -5.49 – -2.84 | 181 | 27.0% | 10 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -1.44 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.05 | – | 0 | – | – | -62 | -62 |
| 2025: Q1 | -1.18 | – | 0 | – | – | -55 | -55 |
| 2025: Q2 | -1.39 | – | 0 | – | – | -77 | -77 |
| 2025: Q3 | -1.70 | – | 0 | – | – | -71 | -71 |
| 2025: Q4 | -1.58 | – | 0 | – | – | -73 | -73 |
| 2026: Q1 | -1.39 | – | 0 | – | – | -92 | -92 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 0 | -10 | -12 | -0.24 | -10 | -17 | 3 |
| 2020 | 0 | -17 | -15 | -0.64 | -15 | -31 | 11 |
| 2021 | 0 | -46 | -46 | -2.13 | -40 | 285 | 294 |
| 2022 | 0 | -86 | -73 | -1.48 | -65 | 463 | 482 |
| 2023 | 0 | -149 | -126 | -2.17 | -100 | 701 | 732 |
| 2024 | 0 | -280 | -261 | -3.93 | -185 | 1,070 | 1,142 |
| 2025 | 0 | -414 | -425 | -5.85 | -275 | 1,248 | 1,413 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Nuvalent, Inc., ein biopharmazeutisches Unternehmen im klinischen Stadium, befasst sich mit der Entwicklung von Therapien für Krebspatienten.
| Employees | 234 |
|---|---|
| Headquarters | Cambridge, MA |
| Address | One Broadway, 02142 Cambridge, United States |
| Phone | 857 357 7000 |
| Website | nuvalent.com |
| IPO Date | 29. Jul 2021 |
| ISIN | US6707031075 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Ruth Adams | Senior Vice President of Clinical Operations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Flynn James E | Director | Other | 3,444 | 124.00 | 427,056 |
| 15. Jul 2026 | Flynn James E | Director | Other | 5,146 | 124.00 | 638,104 |
| 15. Jul 2026 | Flynn James E | Director | Other | 650,000 | 124.00 | 80,600,000 |
| 15. Jul 2026 | Flynn James E | Director | Other | 8,299,225 | 124.00 | 1,029,103,900 |
| 15. Jul 2026 | Meyers Michael L. | Director | Other | 3,444 | – | – |
| 15. Jul 2026 | Meyers Michael L. | Director | Other | 5,146 | 124.00 | 638,104 |
| 15. Jul 2026 | Balcom Alexandra | Chief Financial Officer | Other | 14,350 | – | – |
| 15. Jul 2026 | Balcom Alexandra | Chief Financial Officer | Other | 14,350 | 0.00 | – |
| 15. Jul 2026 | Balcom Alexandra | Chief Financial Officer | Other | 41,100 | – | – |
| 15. Jul 2026 | Balcom Alexandra | Chief Financial Officer | Other | 44,433 | 124.00 | 5,509,692 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.